effect of combined versus monotherapy with deferoxamine and deferiprone in iron overloaded thalassemia patients: a randomized clinical trial

نویسندگان

sasan hejazi department of pediatrics, faculty of medicine, urmia university of medical sciences, urmia, iran.

omid safari department of pediatrics, faculty of medicine, alborz university of medical sciences, karaj, iran.

reza arjmand department of pediatrics, faculty of medicine, alborz university of medical sciences, karaj, iran.

mostafa qorbani department of community medicine, faculty of medicine, alborz university of medical sciences, karaj, iran.

چکیده

background: patients with transfusional iron overload have depended on iron chelation therapy and improving chelation regimens have been of the highest priority. the aim of this study was to compare effect of combined versus monotherapy with deferoxamine (dfo) and deferiprone (dfp) in iron overloaded beta thalassemia (bt) major patients materials and methods we studied 36 bt major patients (mean age 7.6±4.6; range 3–16 years) attending the ormieh motahari hospital for regular transfusional support. patients were randomly allocated to receive one of the following two treatments: dfo in combination with dfp (n=12), dfo alone (n=12) and dfp alone (n=12). serum ferritin level, liver enzymes, blood urea nitrogen, and creatinine and side effects were monitored over a 12 months period. results: after one year, serum ferritin decreased more significantly in patients on dfo+dfp therapy compared to patients who only received dfo or dfp alone (p<0.01). side effects of dfp, including gastrointestinal upset (nausea, vomiting and abdominal pain) and mild agranulocytosis occurred in five (41.7%) and two (8.3%) patients, respectively but none led to discontinuation of the treatment. conclusion: in comparison to the standard chelation monotherapy of dfo, combination treatment with additional dfp reduced serum ferritin and is effective procedure in clinical management of iron overload in patients with bt major.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Effect of Combined versus Monotherapy with Deferoxamine and Deferiprone in Iron Overloaded Thalassemia Patients: a Randomized Clinical Trial

Background: Patients with transfusional iron overload have depended on iron chelation therapy and improving chelation regimens have been of the highest priority. The aim of this study was to compare effect of combined versus monotherapy with Deferoxamine (DFO) and Deferiprone (DFP) in iron overloaded beta thalassemia (BT) major patients Materials and Methods We studied 36 BT major patients (mea...

متن کامل

Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.

Deferiprone has been suggested as an effective oral chelation therapy for thalassemia major. To assess its clinical efficacy, we compared deferiprone with deferoxamine in a large multicenter randomized clinical trial. One-hundred forty-four consecutive patients with thalassemia major and serum ferritin between 1500 and 3000 ng/ml were randomly assigned to deferiprone (75 mg/kg/day) (n = 71) or ...

متن کامل

Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients.

Dear Editor-in-Chief, We shortly report our results of combined iron chelation therapy with deferiprone (DFP) and desferrioxamine (DFX) versus chelation therapy with DFP alone, in iron overloaded β-thalassemia patients. Desferrioxamine has been a life saving iron chelator for thousands of patients in the last 40 years. However, less than 10% of the patients requiring iron chelation therapy worl...

متن کامل

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.

Most deaths in beta-thalassemia major result from cardiac complications due to iron overload. Differential effects on myocardial siderosis may exist between different chelators. A randomized controlled trial was performed in 61 patients previously maintained on subcutaneous deferoxamine. The primary end point was the change in myocardial siderosis (myocardial T2(*)) over 1 year in patients main...

متن کامل

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy

BACKGROUND Due to the limited data available in literature, the aim of this multi-centre study was to prospectively compare in thalassemia major (TM) patients the efficacy of combined deferiprone (DFP) and deferoxamine (DFO) regimen versus either DFP and DFO in monotherapy by cardiovascular magnetic resonance (CMR) over a follow up of 18 months. METHODS Among the first 1135 TM patients in the...

متن کامل

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.

BACKGROUND Cardiac complications secondary to iron overload are the leading cause of death in beta-thalassemia major. Approximately two thirds of patients maintained on the parenteral iron chelator deferoxamine have myocardial iron loading. The oral iron chelator deferiprone has been demonstrated to remove myocardial iron, and it has been proposed that in combination with deferoxamine it may ha...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
international journal of pediatrics

جلد ۴، شماره ۶، صفحات ۱۹۵۹-۱۹۶۵

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023